GRI Bio, Inc.
GRI- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001824293
No open-market purchases or sales by GRI Bio, Inc. insiders were filed in the last 90 days; 11 institutions reported holding it in 13F filings for Q2 2026, worth $164.7K in total; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding GRI Bio, Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 6 | 5 | −1 |
| Shares | 234.2K | 72.8K | −161.5K (−68.9%) |
| Value | $177.2K | $139.7K | −$37.5K (−21.1%) |
New holders (3)
Institutions that held GRI Bio, Inc. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Armistice Capital, LLC | 50,207 | $96.4K | 0.00% |
| BlackRock Inc. | 4,299 | $8.25K | 0.00% |
| Bank of America Corp | 2 | $4 | 0.00% |
Sold out (4)
Institutions that held GRI Bio, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Altium Capital Management LP | 187,981 | $142.9K |
| HRT Financial LP | 19,509 | $14.0K |
| Two Sigma Securities, LLC | 12,701 | $9.65K |
| Wells Fargo & Company | 4 | $3 |